StockData
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc. (ARQT) stock

ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30368% above fair value
$28.26+0.73 (+2.65%)

Close on Nov 13, 2026Market cap $3.55BP/E 128.5Yield –

Earnings

Arcutis Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$143.90M
+45.1% on a year earlier
EPS, Q3 FY2026
$0.06
$0.06 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Arcutis Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$143.90M+45.1%$0.06Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$129.90M+59.4%$0.11Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$129.50M+81.4%$0.13Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025before the open$99.20M+121.4%$0.06Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$81.50M+163.8%-$0.13Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$65.85M+32.8%-$0.20Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025after the close$71.40M+428.9%-$0.09Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close$44.80M+17.6%-$0.33Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024after the close$30.90M+494.2%-$0.42Release
Q1 FY2024ended Mar 31, 2024May 14, 2024after the close$49.57M+1670.3%-$0.32Release
Q4 FY2023ended Dec 31, 2023Feb 27, 2024before the open$13.50M+350.0%-$0.72Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Arcutis Biotherapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
net product salesFY2026$535.00M – $545.00M–NewNov 4, 2026
net product salesFY2026$525.00M – $540.00M$480.00M – $495.00MRaisedAug 5, 2026

Guidance history

Every forecast Arcutis Biotherapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026net product salesFY2026$535.00M – $545.00MNew
Aug 5, 2026net product salesFY2026$525.00M – $540.00MRaised
Feb 25, 2026net product revenueFY2026$480.00M – $495.00MRaised
Oct 28, 2025net product revenueFY2026$455.00M – $470.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Arcutis Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Update
  5. Results
  6. Update
  7. Results
  8. Results
  9. Results
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?